Reverse mutational analysis reveals threonine-373 as a potentially sufficient phosphorylation site for inactivation of the retinoblastoma tumor suppressor protein (pRB)

Cell Cycle

Volumn 5, Issue 15, 2006, Pages 1699-1707

  Lents, Nathan H ^c   Gorges, Laura L ^a   Baldassare, Joseph J ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle; Cyclin A; Cyclin dependent kinase; E2F; Retinoblastoma protein

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN E; THREONINE; TRANSCRIPTION FACTOR E2F; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; REVERTANT;

RODENTIA;

EID: 33747824464     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.15.3126     Document Type: Article

References (76)

1. Hanahan D, Weinberg RA. The Hallmarks of cancer. Cell 2000; 100:57-70.
2. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12.
3. Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2000; 2:E65-7.
4. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10:699-703.
5. Stevaux O, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol 2002; 14:684-91.
6. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-7.
7. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002; 3:11-20.
8. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65:1053-61.
9. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12:2245-62.
10. Cam H, Dynlacht BD. Emerging roles for E2F: Beyond the G1/S transition and DNA replication. Cancer Cell 2003; 3:311-6.
11. Blais A, Dynlacht BD. Hitting their targets: An emerging picture of E2F and cell cycle control. Curr Opin Genet Dev 2004; 14:527-32.
12. Dynlacht BD. E2F and p53 make a nice couple: Converging pathways in apoptosis. Cell Death Differ 2005; 12:313-4.
13. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev 2002; 16:245-56.
14. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995; 15:4215-24.
15. Nevins JR. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258:424-9.
16. Hiebert SW, Blake M, Azizkhan J, Nevins JR. Role of E2F transcription factor in E1A-mediated trans activation of cellular genes. J Virol 1991; 65:3547-52.
17. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin Jr WG, Livingston DM, Orkin SH, Greenberg ME. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85:549-61.
18. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell 1998; 2:293-304.
19. Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, Zhang MQ, Lazebnik Y, Bar-Sagi D, Lowe SW. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002; 4:859-64.
20. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: Distinct E2F proteins mediate activation and repression. Genes Dev 2000; 14:804-16.
21. Wells J, Boyd KE, Fry CJ, Bartley SM, Farnham PJ. Target gene specificity of E2F and pocket protein family members in living cells. Mol Cell Biol 2000; 20:5797-807.
22. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B, Theodorou E, Jacks T. Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization. Genes Dev 2000; 14:3037-50.
23. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle reentry. Nature 2003; 424:223-8.
24. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003; 113:703-16.
25. Narita M, Lowe SW. Executing cell senescence. Cell Cycle 2004; 3:244-6.
26. Dick FA, Dyson N. pRB contains an E2F1-specific binding domain that allows E2F1-induced apoptosis to be regulated separately from other E2F activities. Mol Cell 2003; 12:639-49.
27. Berns A. Timing will tell. Nature 2003; 424:140-1.
28. Ben Porath I, Weinberg RA. When cells get stressed: An integrative view of cellular senescence. J Clin Invest 2004; 113:8-13.
29. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003; 4:181-9.
30. Keenan SM, Lents NH, Baldassare JJ. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression. J Biol Chem 2004; 279:5387-96.
31. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996; 69:247-53.
32. Dhillon NK, Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 2002; 21:4626-34.
33. Dou QP, Pardee AB, Keyomarsi K. Cyclin E - A better prognostic marker for breast cancer than cyclin D? NatMed 1996; 2:254.
34. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54:380-5.
35. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. ProgCell Cycle Res 1997; 3:171-91.
36. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-75.
37. Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 2003; 9:152.
38. Lents NH, Baldassare JJ. CDK2 and cyclin E knockout mice: Lessons from breast cancer. Trends Endocrinol Metab 2004; 15:1-3.
39. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, Sauter G. Cyclin E overexpression and amplification in human tumours. J Pathol 2003; 200:375-82.
40. Leng X, Connell-Crowley L, Goodrich D, Harper JW. S-Phase entry upon ectopic expression of G1 cyclin-dependent kinases in the absence of retinoblastoma protein phosphorylation. Curr Biol 1997; 7:709-12.
41. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993; 73:499-511.
42. Hatakeyama M, Brill JA, Fink GR, Weinberg RA. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev 1994; 8:1759-71.
43. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70:993-1006.
44. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18:753-61.
45. Mittnacht S, Lees JA, Desai D, Harlow E, Morgan DO, Weinberg RA. Distinct subpopulations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J 1994; 13:118-27.
46. Cheng J, Weber JD, Baldassare JJ, Raben DM. Ablation of Go alpha-subunit results in a transformed phenotype and constitutively active phosphatidylcholine-specific phospholipase C. J Biol Chem 1997; 272:17312-9.
47. Weber JD, Hu W, Jefcoat Jr SC, Raben DM, Baldassare JJ. Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem 1997; 272:32966-71.
48. Low DA, Scott RW, Baker JB, Cunningham DD. Cells regulate their mitogenic response to thrombin through release of protease nexin. Nature 1982; 298:476-8.
49. Weber JD, Cheng J, Raben DM, Gardner A, Baldassare JJ. Ablation of Goalpha overrides G1 restriction point control through Ras/ERK/cyclin D1-CDK activities. J Biol Chem 1997; 272:17320-6.
50. Goel R, Phillips-Mason PJ, Raben DM, Baldassare JJ. alpha-Thrombin induces rapid and sustained Akt phosphorylation by beta-arrestin1-dependent and -independent mechanisms, and only the sustained Akt phosphorylation is essential for G1 phase progression. J Biol Chem 2002; 277:18640-8.
51. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, Roberts JM. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 1991; 66:1217-28.
52. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 1993; 13:6501-8.
53. Gardner A, Phillips-Mason PJ, Raben DM, Baldassare JJ. A novel role for Gq alpha in alpha-thrombin-mediated mitogenic signalling pathways. Cell Signal 2002; 14:499-507.
54. Hu W, Bellone CJ, Baldassare JJ. RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity. J Biol Chem 1999; 274:3396-401.
55. Phillips-Mason PJ, Raben DM, Baldassare JJ. Phosphatidylinositol 3-kinase activity regulates alpha-thrombin-stimulated G1 progression by its effect on cyclin D1 expression and cyclin-dependent kinase 4 activity. J Biol Chem 2000; 275:18046-53.
56. Lents NH, Keenan SM, Bellone C, Baldassare JJ. Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2. J Biol Chem 2002; 277:47469-75.
57. Goel R, Phillips-Mason PJ, Gardner A, Raben DM, Baldassare JJ. Alpha-thrombin-mediated phosphatidylinositol 3-kinase activation through release of Gbetagamma dimers from Galphaq and Galphai2. J Biol Chem 2004; 279:6701-10.
58. Harbour JW, Luo RX, Dei SA, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859-69.
59. Chow KN, Starostik P, Dean DC. The Rb family contains a conserved cyclin-dependent-kinase-regulated transcriptional repressor motif. Mol Cell Biol 1996; 16:7173-81.
60. Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, Weinberg RA, Sicinski P. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 1999; 97:767-77.
61. Schulze A, Zerfass K, Spitkovsky D, Middendorp S, Berges J, Helin K, Jansen-Durr P, Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci USA 1995; 92:11264-8.
62. Keenan SM, Bellone C, Baldassare JJ. Cyclin-dependent kinase 2 nucleocytoplasmic translocation is regulated by extracellular regulated kinase. J Biol Chem 2001; 276:22404-9.
63. Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe Jr RT, Griffin RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk L, Veal JM, Walker DH, Kuyper LF. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001; 291:134-7.
64. Lents NH, Keenan SM, Bellone C, Baldassare JJ. Activation and phosphorylation on Thr-160 of nuclear-targeted CDK2 is ERK dependent. Ann NY Acad Sci 2002; 973:265-7.
65. Chiariello M, Gomez E, Gutkind JS. Regulation of cyclin-dependent kinase (Cdk) 2 Thr-160 phosphorylation and activity by mitogen-activated protein kinase in late G1 phase. Biochem J 2000; 349(Pt 3):869-76.
66. Blanchard DA, Mouhamad S, Auffredou MT, Pesty A, Bertoglio J, Leca G, Vazquez A. Cdk2 associates with MAP kinase in vivo and its nuclear translocation is dependent on MAP kinase activation in IL-2-dependent Kit 225 T lymphocytes. Oncogene 2000; 19:4184-9.
67. Chow KN, Dean DC. Domains A and B in the Rb pocket interact to form a transcriptional repressor motif. Mol Cell Biol 1996; 16:4862-8.
68. Harbour JW, Dean DC. Chromatin remodeling and Rb activity. Curr Opin Cell Biol 2000; 12:685-9.
69. Dahiya A, Gavin MR, Luo RX, Dean DC. Role of the LXCXE binding site in Rb function. Mol Cell Biol 2000; 20:6799-805.
70. Roberts JM, Sherr CJ. Bared essentials of CDK2 and cyclin E. Nat Genet 2003; 35:9-10.
71. Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, Rideout WM, Bronson RT, Gardner H, Sicinski P. Cyclin E ablation in the mouse. Cell 2003; 114:431-43.
72. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003; 13:1775-85.
73. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M, Barbacid M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35:25-31.
74. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E, Geng Y, Yu Q, Bhattacharya S, Bronson RT, Akashi K, Sicinski P. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004; 118:477-91.
75. Kozar K, Sicinski P. Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle 2005; 4:388-91.
76. Yu Q, Sicinski P. Mammalian cell cycles without cyclin E-CDK2. Cell Cycle 2004; 3:292-5.